P
Pale Fire Capital SE
+ HältKURA
-0.41%
3-Monats-Rendite
$9.610
-0.244 (-2.54%)Zum Schluss
Loading chart…
- Hoch
- 9.840
- Eröffnung
- 9.800
- Volumengewichteter Durchschnittskurs
- 9.58
- Volumen
- 1.56M
- Marktkap.
- 1.56B
- Tief
- 9.283
- Umsatz
- 14.99M
- EV/EBITDA, TTM
- -1.14
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.
KI-Analyse of Kura Oncology Inc (KURA)
HaltenKura Oncology Inc is not a strong buy at the current price of $9.61 due to its low RSI of 39.012, indicating potential weakness, and significant insider selling activity increasing by 178.01%.
Analystenbewertungen (5)
+209.16% Aufwärtspotenzial
Kaufen
5 Kaufen
0 Halten
0 Verkaufen
Aktuell: 9.61
Tief
16.00
Durchschnitt
29.71
Hoch
40.00
JPMorgan
Übergewichten
$30
2026-10-01
JPMorgan
2026-10-01
Kursziel
$30
Übergewichten
BofA
Kaufen
$31
2026-08-13
BofA
2026-08-13
Kursziel
$31
Kaufen
Lake Street
Kaufen
$23
2026-04-14
Lake Street
2026-04-14
Kursziel
$23
Kaufen
Mizuho
Überdurchschnittlich
$25
2026-03-24
Mizuho
2026-03-24
Kursziel
$25
Überdurchschnittlich
UBS
Kaufen
$15
2026-03-13
UBS
2026-03-13
Kursziel
$15
Kaufen
Bewertungskennzahlen
Das aktuelle erwartete KGV von Kura Oncology Inc (KURA) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -5.65.
Whales, die KURA halten
Event-Zeitleiste
News
9.510-24CNBCBiotech Sector Recovery: Moderna Leads the Charge
8.510-13NewsfilterCaspian and Kura Collaborate on Next-Gen Oral Menin Inhibitor
6.010-01CNBCKura Oncology's Cancer Drug Sales Growth Sparks Stock Rally Potential
6.010-01CNBCLatest Wall Street Rating Updates
- 5.009-04Newsfilter
Kura Oncology Grants Stock Options to New Employees
KURA FAQ – beantwortet von Alphio AI
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Kura Oncology Inc is not a strong buy at the current price of $9.61 due to its low RSI of 39.012, indicating potential weakness, and significant insider selling activity increasing by 178.01%.
5 analysts cover KURA: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 29.71.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.